The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2008 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | RECIIS (Online) |
Texto Completo: | https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848 |
Resumo: | The pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. It’s a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics. |
id |
FIOCRUZ-6_e1c0dd7c17b26544ff1d5104b547087b |
---|---|
oai_identifier_str |
oai:www.reciis.icict.fiocruz.br:article/848 |
network_acronym_str |
FIOCRUZ-6 |
network_name_str |
RECIIS (Online) |
repository_id_str |
|
spelling |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policyA extensão da propriedade intelectual através do sigilo do registro de medicamentos: empecilhos à política de medicamentos genéricosIntellectual propertypatentgenericsdrug registrationpropriedade intelectualpatentegenéricosregistro de medicamentosThe pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. It’s a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics.O setor farmacêutico é caracterizado por um grande oligopólio, com poucas e grandes empresas transnacionais que atuam em diversos países e realizam altos níveis de investimento em pesquisa e desenvolvimento, que implicam em grandes barreiras à entrada de novas empresas. Trata-se de um setor em que a apropriação do conhecimento ocorre principalmente através da patente de novos medicamentos. Tais patentes permitem o monopólio da empresa desenvolvedora do produto sobre o mesmo durante um período determinado. A possibilidade de práticas abusivas a partir deste monopólio leva as autoridades a tomarem medidas para controle de preços e para garantirem a finitude da patente. No entanto, os Estados Unidos e a União Européia vêm pressionando os demais países para o estabelecimento de novas medidas, que vão além do Acordo TRIPS, como o sigilo do registro de medicamenInstituto de Comunicação e Informação Científica e Tecnológica em Saúde (Icict/Fiocruz)2008-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAvaliado pelos paresapplication/pdfapplication/pdfhttps://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/84810.3395/reciis.v2i2.848Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; Vol. 2 No. 2 (2008)Revista Eletrônica de Comunicação, Informação e Inovação em Saúde; Vol. 2 Núm. 2 (2008)Revue de la Communication, de l'Information et de l'Innovation en santé; Vol. 2 No 2 (2008)Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; v. 2 n. 2 (2008)1981-6278reponame:RECIIS (Online)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1490https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1662Hasenclever, LiaParanhos, JuliaPaiva, Vitorinfo:eu-repo/semantics/openAccess2022-08-11T14:24:54Zoai:www.reciis.icict.fiocruz.br:article/848Revistahttps://www.reciis.icict.fiocruz.br/index.php/reciishttps://www.reciis.icict.fiocruz.br/index.php/reciis/oaireciis@icict.fiocruz.br1981-62781981-6278opendoar:2022-08-11T14:24:54RECIIS (Online) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.none.fl_str_mv |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy A extensão da propriedade intelectual através do sigilo do registro de medicamentos: empecilhos à política de medicamentos genéricos |
title |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy |
spellingShingle |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy Hasenclever, Lia Intellectual property patent generics drug registration propriedade intelectual patente genéricos registro de medicamentos |
title_short |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy |
title_full |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy |
title_fullStr |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy |
title_full_unstemmed |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy |
title_sort |
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy |
author |
Hasenclever, Lia |
author_facet |
Hasenclever, Lia Paranhos, Julia Paiva, Vitor |
author_role |
author |
author2 |
Paranhos, Julia Paiva, Vitor |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Hasenclever, Lia Paranhos, Julia Paiva, Vitor |
dc.subject.por.fl_str_mv |
Intellectual property patent generics drug registration propriedade intelectual patente genéricos registro de medicamentos |
topic |
Intellectual property patent generics drug registration propriedade intelectual patente genéricos registro de medicamentos |
description |
The pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. It’s a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics. |
publishDate |
2008 |
dc.date.none.fl_str_mv |
2008-07-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848 10.3395/reciis.v2i2.848 |
url |
https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848 |
identifier_str_mv |
10.3395/reciis.v2i2.848 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1490 https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1662 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Instituto de Comunicação e Informação Científica e Tecnológica em Saúde (Icict/Fiocruz) |
publisher.none.fl_str_mv |
Instituto de Comunicação e Informação Científica e Tecnológica em Saúde (Icict/Fiocruz) |
dc.source.none.fl_str_mv |
Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; Vol. 2 No. 2 (2008) Revista Eletrônica de Comunicação, Informação e Inovação em Saúde; Vol. 2 Núm. 2 (2008) Revue de la Communication, de l'Information et de l'Innovation en santé; Vol. 2 No 2 (2008) Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; v. 2 n. 2 (2008) 1981-6278 reponame:RECIIS (Online) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
RECIIS (Online) |
collection |
RECIIS (Online) |
repository.name.fl_str_mv |
RECIIS (Online) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
reciis@icict.fiocruz.br |
_version_ |
1798942463985975296 |